Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Phase 1b safety run-in study followed by Phase 2 study of ficlatuzumab, azacitidine and venetoclax in untreated Acute Myeloid Leukemia patients aged ≥ 60 years old

Blood (2025) 146 (Supplement 1): 3432.

https://doi.org/10.1182/blood-2025-3432

Published: 2025

Journal Articles

A dose optimization phase 1b/2 study evaluating mipletamig (formerly APVO436), a novel bispecific CD123 x CD3 ADAPTIRÒ molecule in combination therapy for the treatment of frontline acute myeloid leukemia (AML) in patients unfit for intensive chemotherapy

Justin Watts, Gautam Borthakur, Tara Lin, Nashat Gabrail, Kruti Patel, Yazan Madanat, Joshua Zeidner, Noor Khaskhely, Lynn Bonham, Michelle Nelson, John Kumer, Daphne Taylor, Caroline Taromino, Miriam Weber Miller, Dirk Huebner, Michael Maris

Blood (2025) 146 (Supplement 1): 5198.

https://doi.org/10.1182/blood-2025-5198

Published: 2025

Journal Articles

Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study

Blood (2025) 146 (Supplement 1): 453.

https://doi.org/10.1182/blood-2025-453

Published: 2025

Journal Articles

Impact of therapy delays on outcomes in adults with BCR::ABL1 negative b-lineage acute lymphoblastic leukemia (ALL) in the ECOG-ACRIN E1910 trial randomized to conventional chemotherapy +/- blinatumomab

Blood (2025) 146 (Supplement 1): 1549.

https://doi.org/10.1182/blood-2025-1549

Published: 2025

Journal Articles

Toxicities on the E1910 phase III randomized trial of blinatumomab plus chemotherapy in adults with BCR:ABL-1 negative acute lymphoblastic leukemia

Blood (2025) 146 (Supplement 1): 5120.

https://doi.org/10.1182/blood-2025-5120

Published: 2025

Journal Articles

A healthy volunteer study with lomonitinib predicts pharmacokinetics and pharmacodynamics in a relapsed refractory AML study

Blood (2025) 146 (Supplement 1): 6781.

https://doi.org/10.1182/blood-2025-6781

Published: 2025

Journal Articles

Social determinants of health and outcomes in patients with acute leukemia: Interim results from a prospective, single institution study

Maire Okoniewski, Tara Lin, Jianzheng Wu, Ken Byrd, Jesus Gonzalez-Lugo, Dinesh Mudaranthakam, Heather Male

Blood (2025) 146 (Supplement 1): 6403.

https://doi.org/10.1182/blood-2025-6403

Published: 2025

Journal Articles

Treatment responses and survival of newly diagnosed older or unfit patients (pts) with IDH1/2-mutated Acute Myeloid Leukemia (AML): An analysis of the MARROW consortium

Blood (2025) 146 (Supplement 1): 1626.

https://doi.org/10.1182/blood-2025-1626

Published: 2025

Journal Articles

Impact of pre-transplant anxiety and depression on outcomes of AML patients after allogeneic transplantation

Neda Amirmokhtari, Hannah Katz, Elizabeth Muenks, Jianzheng Wu, Joseph McGuirk, Tara Lin

Blood (2025) 146 (Supplement 1): 2851.

https://doi.org/10.1182/blood-2025-2851

Published: 2025

Journal Articles

Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007

Blood (2025) 146 (Supplement 1): 764.

https://doi.org/10.1182/blood-2025-764

Published: 2025

Journal Articles

Characteristics and clinical outcomes of patients (pts) with Acute Myeloid Leukemia (AML) with Mecom rearrangements: An analysis from the MARROW consortium

Blood (2025) 146 (Supplement 1): 294.

https://doi.org/10.1182/blood-2025-294

Published: 2025

Journal Articles

Defining the clinical characteristics and outcomes of adult patients (pts) with 11q23/KMT2A-rearranged Acute Myeloid Leukemia (AML): An analysis from the MARROW consortium

Blood (2025) 146 (Supplement 1): 292.

https://doi.org/10.1182/blood-2025-292

Published: 2025

Journal Articles

RAS mutations negate the favorable impact of NPM1 in older patients with newly diagnosed Acute Myeloid Leukemia treated with ven/HMA

Blood (2025) 146 (Supplement 1): 995.

https://doi.org/10.1182/blood-2025-995

Published: 2025

Journal Articles

Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial

Blood (2025) 146 (Supplement 1): 31.

https://doi.org/10.1182/blood-2025-31

Published: 2025

Journal Articles

Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial

Blood (2020) 136 (Supplement 1): 27–30.

https://doi.org/10.1182/blood-2020-143265

Published: 2020

Journal Articles

A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results

Keith W. Pratz, MD, Mohamad Cherry, MDMS, Jessica K. Altman, MD, Brenda W. Cooper, MD, Jose Carlos Cruz, MD, Joseph G. Jurcic, MD, Mark Levis, MD PhD, Tara Lin, MD, Alexander E. Perl, MD, Nikolai A. Podoltsev, MD PhD, Gary J. Schiller, MD, Jason E. Hill, PhD, Angela James, PhD, Qiaoyang Lu, MS, Ramon V. Tiu, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-137685

Published: 2020

Journal Articles

Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Justin M. Watts, MD, Tara Lin, MD, Eunice S. Wang, MD, Alice S. Mims, MD, Elizabeth H. Cull, MD, Prapti A. Patel, MD, Paul J. Shami, MD, Roland B. Walter, MDPhDMS, Christopher R. Cogle, Ruth A. Chenault, MS, Bret Macpherson, MSc, MBA, Allison Given Chunyk, Catherine J. McMahan, Jane A. Gross, PhD, Scott Stromatt, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-141619

Published: 2020

Journal Articles

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients Enrolled in CPX-351-301, a Randomized Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk and/or Secondary AML

Geoffrey L Uy, MD, Laura F. Newell, MD, Tara Lin, MD, Stuart L. Goldberg, Matthew J. Wieduwilt, MD PhD, Robert J. Ryan, Stefan Faderl, Jeffrey E. Lancet, MD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-136882

Published: 2020

Journal Articles

V-FAST: A Phase 1b Master Trial to Investigate CPX-351 Combined with Various Targeted Agents in Patients with Previously Untreated Acute Myeloid Leukemia

Tara Lin, MD, Gabriel N. Mannis, MD, Harry P. Erba, Mark Levis, MD PhD, Heng Zou, Stefan Faderl, Ronald S. Cheung, Vinod A. Pullarkat, MD

Blood (2020) 136 (Supplement 1): 26–28.

https://doi.org/10.1182/blood-2020-136868

Published: 2020

Journal Articles

First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating Cyad-02, an Optimized Non Gene-Edited Engineered NKG2D CAR T-Cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Dries Deeren, MD PhD, Johan A. Maertens, MD PhD, Tara Lin, MD, Yves Beguin, MD PhD, Benjamin Demoulin, PhD, Martina Fontaine, PhD, Panagiota A. Sotiropoulou, PhD, Erik Alcantar-Orozco, MD, Eytan Breman, Marie-Sophie Dheur, PhD PharmD, Nathalie Braun, Caroline Lonez, PhD, David E Gilham, PhD, Anne Flament, MD, Frédéric F. Lehmann, MD

Blood (2020) 136 (Supplement 1): 36.

https://doi.org/10.1182/blood-2020-139667

Published: 2020

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Phase 1b safety run-in study followed by Phase 2 study of ficlatuzumab, azacitidine and venetoclax in untreated Acute Myeloid Leukemia patients aged ≥ 60 years old

A dose optimization phase 1b/2 study evaluating mipletamig (formerly APVO436), a novel bispecific CD123 x CD3 ADAPTIRÒ molecule in combination therapy for the treatment of frontline acute myeloid leukemia (AML) in patients unfit for intensive chemotherapy

Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study

Impact of therapy delays on outcomes in adults with BCR::ABL1 negative b-lineage acute lymphoblastic leukemia (ALL) in the ECOG-ACRIN E1910 trial randomized to conventional chemotherapy +/- blinatumomab

Toxicities on the E1910 phase III randomized trial of blinatumomab plus chemotherapy in adults with BCR:ABL-1 negative acute lymphoblastic leukemia

A healthy volunteer study with lomonitinib predicts pharmacokinetics and pharmacodynamics in a relapsed refractory AML study

Social determinants of health and outcomes in patients with acute leukemia: Interim results from a prospective, single institution study

Treatment responses and survival of newly diagnosed older or unfit patients (pts) with IDH1/2-mutated Acute Myeloid Leukemia (AML): An analysis of the MARROW consortium

Impact of pre-transplant anxiety and depression on outcomes of AML patients after allogeneic transplantation

Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007

Characteristics and clinical outcomes of patients (pts) with Acute Myeloid Leukemia (AML) with Mecom rearrangements: An analysis from the MARROW consortium

Defining the clinical characteristics and outcomes of adult patients (pts) with 11q23/KMT2A-rearranged Acute Myeloid Leukemia (AML): An analysis from the MARROW consortium

RAS mutations negate the favorable impact of NPM1 in older patients with newly diagnosed Acute Myeloid Leukemia treated with ven/HMA

Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial

Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial

A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results

Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients Enrolled in CPX-351-301, a Randomized Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk and/or Secondary AML

V-FAST: A Phase 1b Master Trial to Investigate CPX-351 Combined with Various Targeted Agents in Patients with Previously Untreated Acute Myeloid Leukemia

First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating Cyad-02, an Optimized Non Gene-Edited Engineered NKG2D CAR T-Cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only